尿激酶联合低分子肝素钙治疗急性心肌梗死临床观察

Clinical observation of urokinase combined with low molecular weight heparin calcium in the treatment of acute myocardial infarction

目的:探讨分析尿激酶联合低分子肝素钙治疗急性心肌梗死的临床疗效。方法:回顾性分析我院于2014年3月~2016年4月接治的86例急性心肌梗死患者的临床资料,按照数字随机法分为两组。治疗组43例,应用尿激酶联合低分子肝素钙治疗;对照组43例,应用尿激酶治疗。治疗1w后,比较两组疗效。结果:治疗组、对照组的总有效率分别为90.70%、69.77%,差异有统计学意义(P<0.05);治疗组的12h血管再通率高于对照组,ST段下降超过50%时间、CK-MB变化时间、胸痛缓解时间均少于对照组,并发症发生率低于对照组,差异均有统计学意义(P<0.05)。结论:尿激酶联合低分子肝素钙治疗急性心肌梗死的临床疗效显著,具有临床推广价值。

Objective： To investigate clinical efficacy of urokinase combined with low molecular weight heparin calcium in the treatment of acute myocardial infarction. Methods： Retrospective analysis of clinical records of 86 cases of acute myocardial infarction in our hospital from March 2014 to April 2016 were randomly divided into two groups according to the number of random method. Treatment group of 43 cases, the application of urokinase combined with low molecular weight heparin calcium treatment; control group of 43 cases, the application of urokinase treatment. After treatment of 1W, the efficacy of the two groups was compared. Results： Before treatment,the two groups showed no significant differences. The treatment group and the control group the total effective rate was 90.70%, 69.77%（P〈0.05）; 12h treatment group vascular reeanalization rate was higher than the control group, ST decreased more than 50% time, CK-MB time, chest pain relief time was less than in the control group, the complication rate was lower than the control group （P〈0.05）. Conclusion：Clinical effect of urokinase combined with low molecular weight heparin calcium in the treatment of acute myocardial infarction is improved markedly.